Table 2.

Association of ABO blood type with outcomes

Multivariable-adjusted analysis assessing association of type-O blood (vs. non-O) with hematoma expansion and neurological outcomes
	HE > 33%a		Hospital-mortalityb		Discharge mRS 4–6b		3 month mRS 4–6b,c
ABO type	N (%)	OR (95% CI); p value	N (%)	OR (95% CI); p value	N (%)	OR (95% CI); p value	N (%)	OR (95% CI); p value
Type-O (n = 146)	28 (19)	0.69 (0.38–1.26); p = 0.23	30 (21)	1.34 (0.67–2.67); p = 0.41	119 (82)	1.22 (0.61–2.46); p = 0.58	95 (65)	1.12 (0.59–2.09); p = 0.73
Non-O (n = 126)	32 (25)		22 (17)		100 (79)		82 (65)
Multivariable adjusted analysis assessing association of ABO blood type (categorical variable) with hematoma expansion and neurological outcomes
	HE > 33%a		Hospital-mortalityb		Discharge mRS 4–6b		3 month mRS 4–6b,c
ABO type	N (%)	OR (95% CI); p value	N (%)	OR (95% CI); p value	N (%)	OR (95% CI); p value	N (%)	OR (95% CI); p value
Type-O (n = 146)	28 (19)	Reference	30 (21)	Reference	119 (82)	Reference	95 (71)	Reference
Type-A (n = 82)	17 (21)	1.11 (0.56–2.24); p = 0.76	11 (13)	0.49 (0.21–1.17); p = 0.11	64 (78)	0.92 (0.40–2.09); p = 0.92	52 (68)	0.87 (0.42–1.80); p = 0.71
Type-B (n = 34)	14 (41)	2.82 (1.23–6.45); p = 0.01	8 (24)	1.39 (0.51–3.78); p = 0.52	28 (82)	0.97 (0.31–3.03); p = 0.96	25 (76)	1.30 (0.47–3.58); p = 0.61
Type-AB (n = 10)	1 (10)	0.48 (0.06–4.13); p = 0.50	3(30)	1.23 (0.23–6.52); p = 0.81	8 (80)	0.76 (0.11–5.19); p = 0.78	5 (71)	0.42 (0.04–4.14); p = 0.46

CI confidence interval, HE hematoma expansion, ICH intracerebral hemorrhage, OR odds ratio, mRS modified Rankin Scale

^aModel adjusted for anticoagulant medication history, time from symptom onset to admission CT, admission ICH volume

^bModel adjusted for ICH score

^c3 month loss to follow-up was 8% (n = 21); percentages of 3 month mRS 4–6 from 251 patients: 146 type O, 82 type A, 34 type B, 10 type AB